🎄 CHRISTMAS DELIVERY ALERT: Order by Midnight, Dec 18th for Pre-Holiday Arrival!
🎄 CHRISTMAS DELIVERY ALERT: Order by Midnight, Dec 18th for Pre-Holiday Arrival!
If you’ve been following the weight loss world, you’ll know that GLP-1 medications like Wegovy and Mounjaro have been making headlines. But there’s something new on the horizon: Orforglipron, a once-daily oral weight loss pill.
Orforglipron is an oral GLP-1 receptor agonist currently being developed by Eli Lilly. Unlike injectable treatments, it’s taken as a simple tablet.
While it’s not yet available in the UK, this medication is another step forward in making effective weight loss treatment more accessible and convenient.
Orforglipron belongs to a class of medications called GLP-1 receptor agonists. These work by mimicking a natural hormone in your body called glucagon-like peptide-1 (GLP-1), which helps regulate your appetite and blood sugar.
When you take oral Orforglipron, it activates GLP-1 receptors in your body, which triggers several effects that support weight reduction:
Reduced appetite: It helps you feel fuller for longer after eating, naturally reducing how much you want to eat throughout the day.
Slower stomach emptying: Food stays in your stomach longer, which prolongs that feeling of fullness and helps prevent overeating.
Better blood sugar control: While primarily used for weight loss, it also helps regulate blood sugar levels by improving how your body responds to food.
Orforglipron is unique because it’s a ‘small molecule’ medication. Unlike injectable GLP-1s like semaglutide or tirzepatide, which are large peptide-based drugs, Orforglipron is a much smaller compound. This is what allows it to be taken as a pill and absorbed effectively through your digestive system.
The medication has a half-life of 29 to 49 hours, which means it stays active in your body long enough to be taken just once daily. This once-daily oral dosing makes it far more convenient than other oral options like Orlistat, which requires you to take it with food.
Orforglipron has been tested in multiple clinical trials, and the results have been promising.
The Phase 1b trial was an early-stage study in people with type 2 diabetes. Over 12 weeks, participants taking Orforglipron lost between 0.24 kg and 5.8 kg, depending on the dose, while those on placebo gained weight. This early trial confirmed Orforglipron was well tolerated.
In the Phase 2 trial published in the New England Journal of Medicine, participants who took Orforglipron for 36 weeks lost between 9.4% and 14.7% of their body weight, depending on the dose.
Those taking the highest dose (45 mg) lost an average of 14.7% of their starting weight. To put that in perspective, someone weighing 100 kg (about 15.7 stone) could lose around 14.7 kg (just over 2 stone).
More recently, the Phase 3 ATTAIN-1 trial showed that after 72 weeks of treatment, people taking the 36 mg dose lost an average of 11.2% of their body weight, compared to just 2.1% in the placebo group. That translates to roughly 27 pounds for someone starting at 245 pounds.
In another Phase 3 trial called ATTAIN-2, which included people with obesity and type 2 diabetes, the 36 mg dose led to an average weight loss of 10.5% (about 23 pounds) over 72 weeks.
People in the trials also saw improvements in waist circumference, blood pressure, cholesterol levels, and other markers of metabolic health. These results show that Orforglipron may offer significant benefits for those on their weight loss journey.
Like other GLP-1 medications, Orforglipron can cause side effects, though most are mild to moderate and tend to improve over time.
The safety profile is consistent with injectable GLP-1 medicines like Wegovy and Mounjaro.
The most common side effects are gastrointestinal, according to the Phase 3 clinical trials, including:
These side effects typically occur during the early weeks of treatment, particularly when starting the medication or increasing the dose. Most people find they settle down as their body adjusts.
In clinical trials, between 4% and 11% of people stopped taking Orforglipron due to side effects, most commonly because of gastrointestinal issues. This is similar to discontinuation rates seen with other GLP-1 medications.
Orforglipron is currently being studied for two main groups of people:
Adults with obesity: In the clinical trials, this included people with a BMI of 30 or above, or a BMI of 27 or above with at least one weight-related health condition (such as high blood pressure, high cholesterol, or sleep apnoea).
Adults with type 2 diabetes: Orforglipron has also been tested in people with type 2 diabetes who need better blood sugar control, whether they have obesity or not.
In the trials, participants typically had a starting weight of around 88-108 kg and an average BMI of around 38. The medication worked well across different doses and in various groups.
Orforglipron hasn’t been studied in:
As with any medication, a doctor must assess whether Orforglipron is right for you based on your health situation, medical history, and current medications. When it becomes available, it will likely be prescribed as part of a weight management programme that includes diet and exercise support.
One of the appealing features of Orforglipron is its simple, once-daily oral dosing. Unlike some oral GLP-1 receptor agonist medications requiring strict fasting rules, Orforglipron can be taken at any time, with or without food or water.
Treatment starts at a low dose and gradually increases over time. This dose escalation approach helps your body adjust to the medication and minimises side effects.
Based on the clinical trials, a typical dosing schedule might look like this:
| Week | Dose |
| Weeks 1-4 | 1 mg once daily |
| Weeks 5-8 | 3 mg once daily |
| Weeks 9-12 | 6 mg once daily |
| Weeks 13-16 | 12 mg once daily |
| Weeks 17-20 | 24 mg once daily |
| Week 21+ | 36 mg once daily (maintenance dose) |
The final maintenance dose depends on how well you tolerate the medication and your treatment goals. In the trials, 12 and 36 mg were most commonly used for long-term weight management.
If you experience side effects at any dose, your doctor may keep you at a lower dose for longer or allow your body more time to adjust before increasing further. In the trials, some people were able to reduce their dose once if needed.
The flexibility of once-daily dosing without food restrictions makes Orforglipron potentially easier to fit into daily life compared to medications that require fasting or weekly injections.
| Medication | Type | Average Weight Loss | Dosing | Food Restrictions |
| Orforglipron (36mg) | Oral tablet | 11.2% in 72 weeks | Once daily | None |
| Wegovy (semaglutide 15mg) | Injection | 14.9% in 68 weeks | Once weekly | None |
| Mounjaro (tirzepatide 15mg) | Injection | 20.9% in 72 weeks | Once weekly | None |
Orforglipron’s weight loss results are respectable but lower than other GLP-1 weight loss injections. Injectable options like Wegovy and Mounjaro produce more dramatic weight loss, but they come with needles, refrigeration requirements, and weekly injections.
Orforglipron offers a simpler alternative – a daily tablet you can take anytime, anywhere, without special storage. For people needle-averse or looking for something that fits easily into their routine, that convenience matters.
See how Mounjaro and Wegovy compare on effectiveness, side effects, and cost to help you make the right choice.
| Medication | Type | Average Weight Loss | How It Works | Food Restrictions |
| Orforglipron | GLP-1 pill | 11.2% at 72 weeks | Reduces appetite and slows stomach emptying | None |
| Oral semaglutide (Rybelsus) | GLP-1 pill | 15.1% in 68 weeks | Reduces appetite and slows stomach emptying | Yes – strict 30-minute fasting required |
| Mysimba | Appetite suppressant pill | 4% in 12 months | Affects brain areas controlling appetite and cravings | None |
| Orlistat (Xenical/Alli) | Fat blocker pill | 2.9% in 12 months | Blocks absorption of dietary fat | Must take with meals containing fat |
Orforglipron stands out among weight loss pills for producing significantly more weight loss than traditional options like Mysimba and Orlistat. It’s also more convenient than oral semaglutide, which requires you to take it first thing in the morning on an empty stomach and wait 30 minutes before eating or drinking anything.
We’ve compared all the leading weight loss tablets to help you find the most effective option for your needs.
Orforglipron is currently in the final stages of clinical testing. Eli Lilly completed its Phase 3 trials in 2025 and announced plans to submit the medication to global regulatory agencies, including the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), by the end of 2025.
If the regulatory review process goes smoothly, Orforglipron could potentially receive approval in the UK sometime in 2026, with a commercial launch following shortly after.
However, these timelines can vary depending on the regulatory review process.
When Orforglipron does become available in the UK, it will likely be prescription-only and may be available through private prescriptions initially before potentially being considered for NHS prescribing.
If you’re interested in weight loss treatments to support your weight loss journey, injectable options like Wegovy and Mounjaro are currently available in the UK through Click2Pharmacy.
Get 10% Off Your First Order
Sign up to receive special offers via email and get 10% off your first order*
By opting in to marketing, you agree to our terms & conditions and privacy policy.
